Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3114694 | 0.92 | KCNH2 (0.42) | KCNH2ALDH1A1GAATSHR | |
| SCHEMBL2541635 | 0.89 | ALDH1A1 (0.45) | KCNH2ALDH1A1GAACA1CA2 | |
| SCHEMBL2541639 | 0.89 | ALDH1A1 (0.45) | KCNH2ALDH1A1GAACA1CA2 | |
| SCHEMBL2361144 | 0.87 | KLK7 (0.38) | KCNH2ALDH1A1GAACA1CA2 | |
| SCHEMBL3111370 | 0.85 | KCNH2 (0.45) | KCNH2 | |
| SCHEMBL2332009 | 0.85 | KCNH2 (0.45) | KCNH2 | |
| SCHEMBL2325928 | 0.85 | KCNH2 (0.45) | KCNH2 | |
| SCHEMBL2360575 | 0.85 | KLK7 (0.37) | KCNH2TSHR | |
| SCHEMBL2535504 | 0.83 | DPP4 (0.47) | KCNH2ALDH1A1GAACA1CA2 | |
| SCHEMBL2543399 | 0.83 | DPP4 (0.47) | KCNH2ALDH1A1GAACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193179-B2 | 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-06-05 | — | — | US | disclosed |
| EP-2167494-B1 | 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-20100179135-A1 | 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179135-A1 | 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ELANE, AAAS, DNPEP | KCNH2 4015/4885ALDH1A1 2312/4885GAA 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.